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Background: Evidence from clinical studies and animal models show that inflammation can lead to the
development of depression. Macrophage migration inhibitory factor (MIF) is an important multifunctional cytokine
that is synthesized by several cell types in the brain. MIF can increase production of other cytokines, activates
cyclooxygenase (COX)-2 and can counter-regulate anti-inflammatory effects of glucocorticoids. Increased plasma
levels of MIF are associated with hypothalamic–pituitary–adrenal (HPA) axis dysregulation and depressive symptoms
in patients. In contrast, MIF knockout (KO) mice have been found to exhibit increased depressive-like behaviour. The
exact role for MIF in depression is therefore still controversial. To further understand the role of MIF in depression,
we studied depressive-like behaviour in congenic male and female MIF KO mice and wild-type (WT) littermates and
the associated neurobiological mechanisms underlying the behavioural outcome.
Methods: MIF KO and WT mice were tested for spontaneous locomotor activity in the open-field test, anhedonia-like
behaviour in the sucrose preference test (SPT), as well as behavioural despair in the forced swim test (FST) and tail
suspension test (TST). Brain and serum levels of cytokines, the enzymes COX-2 and indoleamine-2,3-dioxygenase
(IDO) and the glucocorticoid hormone corticosterone were measured by RT-qPCR and/or high-sensitivity
electrochemiluminescence-based multiplex immunoassays. Monoamines and metabolites were examined using HPLC.
Results: We found that MIF KO mice of both sexes displayed decreased depressive-like behaviour as measured in the
FST. In the TST, a similar, but non-significant, trend was also found. IFN-γ levels were decreased, and dopamine
metabolism increased in MIF KO mice. Decreased brain IFN-γ levels predicted higher striatal dopamine levels, and high
dopamine levels in turn were associated with reduced depressive-like behaviour. In the SPT, there was a sex-specific
discrepancy, where male MIF KO mice showed reduced anhedonia-like behaviour whereas female KO mice displayed
increased anhedonia-like behaviour. Our results suggest that this relates to the increased corticosterone levels detected
in female, but not male, MIF KO mice.
Conclusions: Our findings support that MIF is involved in the generation of depressive-like symptoms, potentially by
the effects of IFN-γ on dopamine metabolism. Our data further suggests a sex-specific regulation of the involved
mechanisms.
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Depression is a severe and debilitating disease and the
lifetime prevalence for major depressive disorder has in
some populations been reported to be more than 20 %
[1]. Current antidepressant medication primarily focuses
on modulating the monoamine neurotransmitter sys-
tems which only provide sufficient symptom relief to
approximately half of the patients [2, 3]. This emphasizes
the need for a better understanding of the disease to be
able to develop new and improved treatment strategies.
Recently, it has been suggested that inflammation may
play a key role in the pathophysiology of depression. It has
been known for several years that patients without psychi-
atric history, who receive injections of pro-inflammatory
substances (interferons) as treatment for certain forms of
cancer, develop depression and suicidality at an increased
rate [4–7]. Furthermore, depressive symptoms appear in
both humans and animal models when cytokine levels
are experimentally elevated by injections of the bacter-
ial endotoxin lipopolysaccharide [8–10]. Interestingly,
patients with primary depression (e.g. with no known
underlying somatic cause) also have elevated plasma
levels of pro-inflammatory cytokines [11–13], and it has
even been shown that treatment with anti-inflammatory
drugs can alleviate symptoms in depressed patients as
measured with the Hamilton Depression Scale [14].
Macrophage migration inhibitory factor (MIF) is an
important multifunctional cytokine that is synthesized
by several cell types in the brain and is expressed in
brain areas associated with the behavioural symptoms
of depression [15]. MIF is upregulated in diseases with an
inflammatory component, such as cancer, obesity and type
2 diabetes. Further, MIF induces expression of the key
pro-inflammatory receptor Toll-like receptor 4 [16, 17],
activates cyclooxygenase (COX)-2 [18] and has also been
found to counter-regulate the anti-inflammatory effects of
glucocorticoids [19–21]. It has also been shown that MIF
can increase the cytokine levels of TNF-α, IL-1β and IL-6
[22, 23] which have all been associated with depression.
Correspondingly, it has been shown that MIF inhibition
leads to downregulation of TNF-α and IFN-γ [24].
A link between MIF and depression has already been
suggested but its exact role is still under debate [15]. Clin-
ical studies have found that serum levels of MIF are in-
creased in depressed patients [25] and correlate positively
with depressive symptoms as measured with the Beck
Depression Inventory short form [26]. Non-responding
depressed patients display increased blood levels of MIF
mRNA, and antidepressant drugs decrease the blood
levels of this cytokine [27]. In line with these clinical find-
ings, an animal model has shown that 4, 8, 12 or 16 weeks
of unpredictable chronic mild stress all increases levels of
MIF and can lead to depressive-like behaviour [28].
Together, these results indicate that higher levels of MIFare associated with more severe depressive and depressive-
like symptoms. Therefore, MIF could potentially constitute
a target for future anti-depressive treatments. However, the
role of MIF in depression is still controversial as an experi-
mental study showed that MIF KO mice exhibited a higher
degree of depressive-like behaviour compared to WT
controls as measured using the forced swim test (FST)
[29], and another study indicated that the anti-depressive
effects of voluntary wheel-running exercise are mediated
by increased production of MIF [30].
As evident from the above, the effects of MIF and
MIF deletion on depressive-like behaviour and the
underlying mechanisms involved need to be character-
ized in detail. In the studies presented here, we aimed
to further elucidate the role of MIF in depressive-like
behaviour by the use of congenic male and female MIF
KO mice and WT littermates. As human depression is
a multimodal disease, there is no single test for rodent
behaviour that reflects human depression. We assessed
the effects of MIF deletion on rodent behaviour utiliz-
ing a battery of validated behavioural tests, including
the FST, the tail suspension test (TST) and the su-
crose preference test (SPT) [31]. The TST and FST
are both validated models of behavioural despair in
mice. The term “behavioural despair” is used, as it is
believed that immobility in this test reflects that the
animals have “given up hope of escaping” [32].
Although TST and FST share a common theoretical basis,
there are differences between them, and they therefore
complement each other. For example, TST avoids prob-
lems of hypothermia or motor dysfunction that could
interfere with the performance in the swim test, while the
FST could overcome the tail climbing problem in the TST
[33]. The SPT is a measure of anhedonia-like behaviour;
when given a choice of drinking either a sucrose solution
or water, rodents will choose to drink the sucrose solution.
Animals that do not show this preference are believed to
display anhedonia-like behaviour [34]. We selected these
behavioural tests to be able to assess both behavioural des-
pair as well as anhedonia-like behaviour.
In addition to testing for depressive-like behaviour, we
analysed spontaneous locomotor activity in the open-field
test. Spontaneous locomotor activity was examined to
determine that the animals did not display motor abnor-
malities that could be a confounding factor when evaluat-
ing the outcome of the FST. Moreover, in order to further
understand the underlying neurobiological changes,
we analysed the relation of inflammatory factors and
monoamine metabolism to the observed behaviour.
Materials and methods
Animals
Adult congenic MIF−/− (KO) mice and MIF+/+ (WT)
littermates on a C57BL/6 background were used for
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matched in all experiments and randomised so that
both siblings as well as non-siblings were found in each
experimental group. The animals were bred and housed
at Lund University, Sweden. Genotype was determined
by PCR using primers as previously reported [35]. The
animals were housed two to six per cage in standard
laboratory cages with sawdust bedding, enrichment
material and free access to water and food. The holding
room had a 12:12 light–dark cycle (light on at 7.00 am).
Body weights were monitored throughout the experi-
ment, and all procedures were performed in accordance
with national and local laws and were approved by the




We examined depressive-like behaviour in our animal
model by means of the SPT, the FST and the TST. On day
1–8, the animals went through the SPT. On day 4, the
habituation for the open field test (OFT) was performed
and on day 6, the locomotor activity test. The FST was
performed on day 8 and TST 24 h after, on day 9. Number
of animals per behavioural group was ≥7 in all groups.
Open-field test
To ascertain that the animals did not suffer from any
gross locomotor disturbances, spontaneous activity in
the OFT was assessed. The experiment consisted of a
habituation trial of 6 min followed 48 h after by the 6-
min test. The OFT was a white Plexiglas box of 45 ×
45 cm with 40 cm high walls, and the total distance
moved was recorded using the SMART tracking soft-
ware (Panlab, Harvard apparatus, Spain). Twelve male
WT, 10 female WT, 16 male KO and 16 female KO ani-
mals went through the OFT.
Forced swim test
Stillness, a measure of behavioural despair, was examined
in the FST for 6 min, using clear Plexiglas cylinders
(25 cm high, ø 20 cm) which were filled with 25 °C water
to a depth where the animals could not touch the bottom
with their tails [36]. Stillness was assessed using SMART
tracking software (Panlab, Harvard apparatus, Spain).
Eight male WT, 7 female WT, 8 male KO and 8 female
KO mice went through the FST.
Tail suspension test
The TST apparatus was a white Plexiglas box with one
open side (30 cm × 20 × 20) which in the middle of the
ceiling had a hook attached. Adhesive tape was attached
to the tail of the mouse (approximately 1 cm away from
the tip of the tail), and the mouse was then suspendedfrom the hook in the ceiling, for 10 min [37, 38]. The
behaviour of the animal was recorded with a video
camera, and stillness was subsequently rated blindly.
Eight male WT, 7 female WT, 8 male KO and 8 female
KO mice went through the TST, but one animal had to
be excluded as it performed tail climbing and therefore
correct behaviour could not be evaluated.
Sucrose preference test
For the SPT, animals were placed in separate cages, with
access to two bottles; one containing tap water and the
other a 2 % sucrose solution, for 5 h every day and for
8 days during the wake period of the animals’ diurnal
cycle. The bottles were counterbalanced to avoid side
preferences. Percent sucrose preference was calculated as
sucrose consumption gð Þ  100
sucrose consumption gð Þ þ water consumption gð Þ . Twelve male WT,
10 female WT, 16 male KO and 16 female KO animals
underwent the SPT.
Termination and sample preparation
After the last behavioural test, animals were deeply anes-
thetized with pentobarbital (100 mg/kg) and blood was
collected from the heart. Brain regions of interest were
immediately isolated on ice, snap-frozen on dry ice and
thereafter stored at −80 °C until further analysis.
Reverse transcription quantitative PCR (RT-qPCR)
RNA from brain tissue (hippocampus and pre-
frontal cortex (PFC)) was extracted using Trizol
reagent (Invitrogen, Sweden) followed by RNeasy mini
kit (Qiagen, Germany), according to the manufac-
turer’s instructions. One microgram of total RNA was
reverse transcribed into cDNA using Super-Script III
(Invitrogen, Sweden) following the manufacturer’s
instructions. RT-qPCR was conducted on a C1000
thermal cycler with CFX 96 real-time system (Bio-Rad,
Sweden) using Maxima SYBRgreen qPCR Mix (Fermentas,
Sweden) in a 20 μl reaction with Hprt1 and Ppia as
the control genes. All samples were run in triplicates.
The following mRNA sequences were examined: IL-1β,
IL-6, TNF-α, IFN-γ, IDO1 and COX-2. IFN-γ was
undetectable using RT-qPCR for a total of ten sam-
ples (1 male WT, 3 female WT, 3 male KO, 3 female
KO). These samples were assigned a Ct value of 40.
Primer sequences are found in Table 1. Data were
analysed using the Pfaffl method [39]. Tissue from 8
male WT, 7 female WT, 8 male KO and 8 female KO
animals was available for RT-qPCR experiments.
Detection of cytokines
Cytokines were quantified in blood serum using high-
sensitivity electrochemiluminescence-based multiplex
immunoassay (MesoScale Discovery, USA). We used


















Fig. 1 Immobility time (s/6 min) in the forced swim test. Columns
represent mean + SEM. ***p < 0.001 compared to WT animals (ANOVA)
(n = 7–8 per group)
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kit to measure IL-6, IL-1β, KC/GRO, IFN-γ, IL-10,
IL12p70 and TNF-α (Meso Scale Discovery, Rockville,
USA). Fifty-microliter reactions were carried out, and
the multiplex plates were analysed on a SECTOR 6000
instrument following the manufacturer’s instructions.
All samples were run in duplicates. Serum from 12
male WT, 10 female WT, 16 male KO and 16 female
KO was available for the multiplex immunoassay. For
one assay, IL-1β was not detectable due to technical
issues and therefore, IL-1β was detected in serum from
only 9 male WT, 3 female WT, 8 male KO and 4 female
KO animals.
High-performance liquid chromatography
Monoamine neurotransmitters and their metabolites
were examined in the striatum of the animals using
high-performance liquid chromatography (HPLC) as
described previously [40]. These included dopamine
(DA) and its metabolites 3,4-dihydroxyphenylacetic acid
(DOPAC) and homovanillic acid (HVA), serotonin (5-HT)
and its metabolite 5-hydroxyindoleacetic acid (5-HIAA)
and norepinephrine (NE) and its metabolite 3-methoxy-4-
hydroxyphenylglycol (MHPG). Striatal tissue from 12 male
WT, 8 female WT, 16 male KO and 15 female KO animals
was available for the HPLC analyses.
Corticosterone assay
Corticosterone was quantified using a commercially
available assay (DetectX, Arbor Assays, USA). Fifty mi-
croliters of blood serum was used, and all samples were
run in duplicates. The assay was performed according tothe manufacturer’s instructions. Serum was available from
8 male WT, 6 female WT, 10 male KO and 7 female KO
animals for the corticosterone assay.
Statistical analysis
Statistical analysis was performed using SPSS 19 software.
For all analysis, 2 × 2 univariate ANOVAs were performed
and when appropriate, i.e. when a significant interaction
between genotype and sex was found, this was followed by
planned comparisons Student’s independent t-tests com-
paring genotype within each sex. Non-normally distrib-
uted data were ln transformed. Linear regression models
were used to investigate the impact of the concentration
of biological analytes on behavioural outcomes. Correl-
ation analysis was performed using Pearson’s r. Alpha level
of significance was set at p < 0.05.
Results
Effects of MIF deletion on behaviour
MIF KO mice show decreased behavioural despair
In the FST, KO animals of both sexes were signifi-
cantly less immobile than WT littermates, indicating
a lower level of depressive-like behaviour in the KO mice
(Fig. 1). There was an effect of genotype (F(1,27) = 14.784,
p = 0.001) and sex (F(1,27) = 9.822, p < 0.01) with males
being less immobile than females independent of genotype
(genotype × sex interaction (F(1,27) = 2.374, NS)).
In the TST, a non-significant trend towards a genotype
effect was also found (F(1,26) = 3.946, p = 0.058), with
KO animals showing less immobility compared to WT
controls, which is in line with the FST results above
(Fig. 2).
Increased sucrose preference in male MIF KO mice
In the SPT, we found an effect of genotype (F(1,50) = 4.295,
p < 0.05) and a genotype × sex interaction (F(1,50) = 35.731,
p < 0.001). Post hoc comparisons showed that male MIF
KO mice had an increased preference for sucrose com-
pared to WT animals, indicating that they also in this test
Fig. 2 Immobility time (s/10 min) in the tail suspension test. Columns
represent mean + SEM. (n = 7–8 per group)
Fig. 4 Spontaneous locomotor activity in the open field (cm/6 min)
in MIF KO compared to WT littermate controls. Columns represent
mean + SEM. *p < 0.05 compared to WT animals (ANOVA) (n = 10–16
animals per group)
Bay-Richter et al. Journal of Neuroinflammation  (2015) 12:163 Page 5 of 11demonstrated a lower degree of depressive-like behaviour.
In contrast, female MIF KO mice showed less preference
for sucrose than the WT females (see Fig. 3).
MIF KO mice display slight hypolocomotion in the
open-field test
Locomotor activity in the OFT was performed to evalu-
ate motor performance of the MIF KO mice compared
with WT littermates, which is important for the FST
interpretation. An effect of genotype (F(1,50) = 6.143,
p < 0.05) and sex (F(1,50) = 11.667, p = 0.001) but no
genotype × sex interaction (F(1,50) = 1.606, NS) was
found. As can be seen in Fig. 4, MIF KO animals
showed a slightly decreased locomotor activity in the
OFT compared to WT. Despite the lack of a significant
genotype × sex interaction, the decrease in locomotor
activity appears primarily in female animals. The decreased
spontaneous locomotor activity in the OFT did not con-
found the performance in the FST, as MIF KO animals
were found to move significantly more in the FST test than
WTcontrols.
Food intake is unaltered in MIF KO mice
To examine whether caloric intake differed between the
experimental groups, food intake was also measured. NoFig. 3 Percent sucrose preference in the sucrose preference test.
Columns represent mean + SEM. *p = 0.05, ***p < 0.001 compared to
the WT group of same sex in post hoc t tests (n = 10–16 animals
per group)difference was found (all F values <0.03). In addition,
bodyweights did not differ between genotype (all F
values <2).
MIF deletion causes sex-specific alteration of IFN-γ mRNA
expression
Reverse transcriptase qPCR on prefrontal cortex (PFC
tissue) showed an altered IFN-γ mRNA expression in
KO mice compared to WT mice and that this expression
differed between the sexes. This was found as the 2 × 2
univariate ANOVA revealed an interaction between
genotype and sex for IFN-γ mRNA expression in the
PFC (F(1,25) = 4.457, p < 0.05). This suggests that the
alteration of IFN-γ expression caused by MIF deletion is
sex specific (Fig. 5). Post hoc comparisons were non-
significant, but the tendency is towards a decreased
mRNA expression of IFN-γ in male KO mice and pos-
sibly an increased IFN-γ expression in female KO mice.
In the hippocampus, the mRNA expression of IFN-γ
was also altered; here, KO mice of both sexes displayed
a lower mRNA expression than WT animals. This was
revealed in the 2 × 2 univariate ANOVA, where an effect
of genotype (F(1,27) = 4.346, p < 0.05) as well as sex
(F(1,27) = 5.383, p < 0.05) was found. MIF KO animals
had lower expression of IFN-γ in the hippocampus, and
the females had lower expression than in males (Fig. 5b).
The expression of mRNA for all other cytokines exam-
ined, COX-2 or IDO (see Table 1) were not altered in
MIF KO compared to WT animals (all F’s <1.0).
Similar changes were found in the peripheral blood
serum for IFN-γ. Here, as seen in the PFC, IFN-γ
levels were found altered in KO mice compared to
WT mice and this effect differed between sexes. This
was found in the 2 × 2 univariate ANOVA where a
significant genotype × sex interaction was revealed
(F(1,16) = 4.788, p < 0.05). As can be seen in Fig. 6,
MIF KO males appear to display lower levels of IFN-γ
ab
Fig. 5 Normalized fold mRNA expression of IFN-γ in MIF KO and WT
mice in the a prefrontal cortex and b hippocampus. Columns represent
mean + SEM. *p < 0.05 compared to WT animals (ANOVA) (for (a),




Bay-Richter et al. Journal of Neuroinflammation  (2015) 12:163 Page 6 of 11than their WT littermates. Interestingly, the female
MIF KO mice displayed higher levels of IFN-γ in the
blood compared to their WT counterparts. No significant
genotype effects were found for other serum cytokines (all
F’s <3.5).
The effect of MIF deletion on monoamine metabolite
levels
Levels of the dopamine metabolite HVA differed between
WT and KO animals, and this difference was dependent
of sex; male KO mice displayed slightly increased levels of
HVA whereas female KO mice displayed decreasedFig. 6 Blood serum expression (pg/ml) of IFN-γ. Columns
represent mean + SEMlevels of HVA. The 2 × 2 univariate ANOVA showed
that a significant genotype × sex interaction (F(1,47) =
6.418, p = 0.01) was present as well as a sex effect
(F(1,47) = 6.609, p = 0.01), with females, independent
of genotype, displaying higher levels of HVA. No over-
all genotype effect was found (F < 0.3). For DOPAC,
the pattern was similar; DOPAC differed between WT
and KO animals and this difference was dependent of
sex; male KO mice displayed slightly increased levels
of DOPAC whereas female KO mice displayed
decreased levels of DOPAC as evident by the signifi-
cant genotype × sex interaction (F(1,47) = 4.171, p < 0.05).
No overall genotype or sex effects (F’s <2.5) were found
(Fig. 7a, b). No significant differences between groupsFig. 7 Monoamine metabolite levels in the striatum from WT and
MIF KO animals. a HVA, b DOPAC and c 5-HIAA expression. Columns
represent mean + SEM. ***p < 0.001 compared to the WT group of
same sex in post hoc t tests (n = 8–16 animals per group)
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specific changes for HVA and DOPAC but not for DA.
The levels of the serotonin metabolite 5-HIAA were
altered in MIF KO mice. Overall, MIF KO mice dis-
played reduced levels of this metabolite, this effect pri-
marily being driven by a marked decrease in the female
KO animals, suggesting that MIF deletion in female mice
have a specific effect on serotonin metabolites. A signifi-
cant genotype (F(1,47) = 10.900, p < 0.01), sex (F(1,47) =
18.720, p < 0.001) and a genotype × sex interaction
(F(1,47) = 12.582, p < 0.001) was found. MIF KO females
showed a statistically significant decrease in 5-HIAA
compared to WT females (Fig. 7c).
Association between monoamines, inflammation and
behaviour
DA levels correlated negatively with immobility in the
FST in all animals (r = −0.380, p < 0.05) indicating that
higher levels of DA are associated with the reduced
depressive-like behaviour observed in the MIF KO mice
(see Fig. 8a).
The inflammatory cytokines IFN-γ and IL-1β levels
correlated positively with HVA levels (r = 0.346, p = 0.01;a
c
Fig. 8 a Immobility in FST versus striatal DA levels, b correlation between s
and striatal HVA levels and d correlation between striatal 5-HIAA and sucror = 0.446, p < 0.05) showing a relationship between the
degree of inflammation and dopamine metabolism
(Fig. 8b, c). In a linear regression model including sex
and genotype, we found that the serum concentration
of IFN-γ was a significant predictor of striatal DA
levels (β = 0.148; p < 0.05), where high levels of IFN-γ
corresponded to low DA levels in the striatum.
We also found a positive relationship between sucrose
preference and 5-HIAA in all animals (r = 0.328, p = 0.01)
(Fig. 8d). Female MIF KO mice displayed low 5-HIAA
levels and also exhibited decreased sucrose preference, as
mentioned previously. The reduced 5-HIAA could thus
possibly represent a biological mechanism involved in this
behavioural change observed in the female MIF KO mice
(see Figs. 3 and 7c).The effect of MIF deletion on corticosterone levels
For blood serum levels of corticosterone, a significant
genotype × sex interaction was found (F(1,35) = 4.326,
p < 0.05). Female MIF KO mice had significantly ele-
vated corticosterone levels compared to their WT
counterparts (Fig. 9).b
d
erum IFN-γ and striatal HVA levels, c correlation between serum IL-1β
se preference
Fig. 9 Corticosterone concentration (ng/mL) in MIF WT and KO
animals. Columns represent mean + SEM. *p < 0.05 compared to WT
equivalents (n = 7–14 animals per group)
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In summary, we show that deletion of the MIF gene led
to reduced behavioural despair in mice of both sexes, as
assessed in the FST and with a similar trend in the TST.
The IFN-γ mRNA levels were reduced in the hippocam-
pus of the MIF KO mice, and sex-specific alterations of
IFN-γ in the PFC and blood serum were found. Moreover,
we observed significant changes in the monoamine- and
monoamine metabolite levels in the MIF KO mice.
Importantly, lower serum IFN-γ levels predicted higher
DA levels, and the DA levels were directly associated with
the reduced behavioural despair in the FST in all animals.
The results we observed in the TST were very similar to
the results in the FST, although they were only trending
towards significance. Thus, in this study we have detected
a reduced behavioural despair by deleting the MIF gene.
The effect was mediated by decreased levels of IFN-γ,
which predicted higher levels of brain dopamine.
Our finding that the MIF KO mice displayed reduced
depressive-like behaviour in the FST is paralleled by
recent clinical findings. Elevated plasma MIF levels have
been shown to be associated with higher depression
scores in otherwise healthy subjects as measured by the
Beck Depression Inventory short form [26], and in preg-
nant women, higher depression scores assessed using
the Center for Epidemiologic Studies Depression Scale
were also associated with elevated MIF levels after influ-
enza vaccination [41]. Furthermore, patients suffering
from major depressive disorder (MDD) had elevated
levels of MIF compared to healthy controls [25]. Re-
cently, Cattaneo and colleagues studied a group of pa-
tients suffering from MDD and measured mRNA levels
of several cytokines in serum leukocytes. They found
increased MIF mRNA levels at baseline in patients, and
moreover that MIF levels decreased more than other
measured cytokines during treatment [42]. Although
ample clinical data support a role of MIF in depression,
one study failed to find any connection between bloodserum levels of MIF and depressive symptoms assessed
by the Zung Self-Rating Depression Scale in a cohort of
209 healthy medical students [43].
This current study is the first time that sex-specific
effects of MIF deletion have been assessed at the behav-
ioural and neurobiological level. Interestingly, we found
a sex-specific effect of the MIF KO in the sucrose prefer-
ence test. Male MIF KO animals showed increased
sucrose preference, whereas females showed decreased
sucrose preference compared to the WT littermates.
This behavioural discrepancy between the sexes was
paralleled by an increase in plasma corticosteroids
and lower brain levels of 5-HIAA in the female mice
than their WT counterparts. Clinical depression can
be stress-related and increased levels of glucocorticoid
hormones such as cortisol have been closely related
to the pathogenesis of depression [44, 45]. Chronically
elevated cortisol levels and hypothalamic–pituitary–
adrenal (HPA) axis hyperactivity is associated with
reduced hippocampal size as well as reduced brain 5-
HT synthesis and low CSF 5-HIAA levels [46]. Such
changes are believed to be associated with depression.
Further, it has been suggested that females are more
likely to experience an imbalance in plasma levels of
cortisol due to hormonal changes during the menstrual
cycle [47]. The rodent equivalent of cortisol is cortico-
sterone. MIF is known to counter-regulate glucocorticoid
action that reverses glucocorticoid-induced immunosup-
pression and, in particular, glucocorticoid-induced pro-
inflammatory cytokine inhibition [48]. Our present results
show that female MIF KO mice displayed significantly in-
creased corticosterone levels. Such increase could underlie
some of the observed sex differences caused by the MIF
deletion, including the sex-specific decrease in 5-HIAA
seen in female KO mice. Further, we see a positive correl-
ation between 5-HIAA levels and sucrose preference. The
increased corticosterone levels and subsequent decrease
in 5-HIAA could therefore be the underlying factor for
the sex difference seen in the SPT. We here studied the
effect of MIF deletion on circulating corticosterone levels.
Female MIF KO mice displayed significantly increased
corticosterone levels, indicating that HPA axis activation
could underlie some of the observed gender differences
caused by the MIF deletion.
The decreased sucrose preference in female mice is in
line with findings in MIF-KO mice by Conboy and col-
leagues [29]. In addition to a decreased sucrose prefer-
ence, the study by Conboy and colleagues also reports
increased immobility in the FST [29], which is in con-
trast to our findings in the current report. A difference
between these two studies is that in our present study,
WT littermates serve as controls whereas in the Conboy
et al. [29] study, control animals were obtained from a
commercial breeding facility. Importantly, the sex of the
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to our knowledge, our current study is the first to exam-
ine the behavioural effects of MIF deletion in both sexes.
It is worth mentioning that the baseline stress between
litters of mice, experimental time point and different
laboratories can also affect the outcome of animal
behaviour in general, and particularly the outcome of
depressive-like behaviour [49]. Further, a limitation with
this and other studies using constitutive KO animals is
that compensatory mechanisms such as up- or downregu-
lation of genes cannot be completely excluded. To further
elucidate this, experiments using conditional MIF KO
mice should be performed.
Hitherto, most experiments have been performed
solely in male animals although recent guidelines from,
e.g. NIH, now encourage the use of both sexes in pre-
clinical experiments [50]. The results presented here
stress the importance of an approach using both male
and female animals, as distinct sex differences were
found. The sex-based differences observed in this study
are moreover in line with recent reports showing that
female MIF KO mice have larger infarcts and increased
microglial activity than WT females and male MIF KO
mice after experimental stroke [51]. An important differ-
ence between male and female mice was the increased
levels of corticosterone in female MIF KO mice, indicat-
ing that these animals have a dysregulated HPA axis.
Indeed, corticosterone is known downregulate the ex-
pression of the cell survival gene Bcl-2 that is important
for stroke outcome [52].
We found evidence of reduced IFN-γ expression both
in the brain and in the blood of MIF KO animals. Sup-
porting these results, it has been shown that MIF inhib-
ition downregulates the in vivo secretion of IFN-γ
measured in spleen mononuclear cells, harvested from
mice following 14 days of treatment with a MIF inhibitor
[24]. IFN-γ could be an important link between MIF and
depressive-like behaviour, as it is known that IFN-γ ad-
ministration can induce depressive symptoms in
humans and depressive-like behaviour in animals, pos-
sibly through the activation of the enzyme IDO and
thereby the kynurenine pathway which is thought to be
related to depression [53]. Patients treated with IFN as
a therapy against hepatitis and certain forms of cancer
develop depression and suicidality at a significantly
increased rate [5, 54]. Moreover, postmortem studies of
depressed patients showed increased IFN-γ expression in
the Brodmann Area 10 (anterior PFC) [55]. Psychiatric
symptoms have been shown to be associated with an IFN-
γ gene (+874) T/A gene polymorphism, as hepatitis C
patients treated with interferons were more likely to
experience depressive symptoms when they had the T
(high producer) allele of IFN-γ (+874) gene than patients
with the A (low producer) allele [56]. In an animal model,BCG-induced depressive-like behaviour was completely
abolished in IFN-γ KO mice [57]. Therefore, IFN-γ might
be a key player in the development of depressive-like
behaviour. Interestingly, our results indicate a specific
role of IFN-γ connected to the MIF deletion, as the
other measured cytokines did not differ between WT
and KO animals.
We found that the positive effects on depressive-
like behaviour in the MIF KO mice were predicted by
higher levels of dopamine. In other words, the striatal
dopamine content was positively associated with the
reduced behavioural despair in the FST. Interestingly,
a role of IFN-γ in regulating dopamine levels and
dopamine metabolism has previously been reported. IFN-
γ indirectly reduces the biosynthesis of dopamine by
impairing the oxidation-labile 5,6,7,8-tetrahydrobiopterin,
which is rate-limiting for the biosynthesis of dopamine
[58]. It is therefore possible that decreased levels of IFN-γ,
as seen in the male MIF KO mice, led to a decreased
metabolism of dopamine in the male MIF KO mice and
consequently higher dopamine levels in these mice.
Reduced dopamine levels in the midbrain are associated
with depressive-like behaviour, for example, as seen by
optogenetic stimulation and inhibition of VTA dopamine
neurons [59–61]. In other words, altered expression of
IFN-γ could not only lead to both an activation of IDO
and the kynurenine pathway implicated in depression, but
also to significant changes in the brain dopamine content.
We therefore suggest that the observed changes in IFN-γ
expression could be a key mechanism responsible for the
effects of MIF deletion on behaviour.
Conclusions
Several reports suggest that MIF is implicated in depres-
sion, but its exact biological contribution to the disease
is under debate [15]. In this study, we have shed light on
possible biological mechanisms by which MIF deletion
could impact depressive-like behaviour in rodents. In
summary, we found that mice with a genetic deletion of
the MIF gene displayed reduced depressive-like behav-
iour in the FST. Our results suggest that in the absence
of MIF, IFN-γ expression is reduced, which in turn af-
fects the biosynthesis of dopamine, leading to increased
levels of dopamine metabolites. The dopamine levels
were associated with the behavioural changes. For the
first time, we also demonstrate sex-specific effects of the
MIF deletion, as female MIF KO mice displayed de-
creased sucrose preference. The behavioural changes in
the female MIF KO mice were paralleled by increased
corticosteroids and decreased brain 5-HIAA. Thus, our
results suggest that MIF has a role in promoting
depressive-like behaviours in rodents, and further stresses
the importance of examination of sex differences in ani-
mal models of depression.
Bay-Richter et al. Journal of Neuroinflammation  (2015) 12:163 Page 10 of 11Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
CBR, TD and LB conceived the study. CBR designed and performed the
experiments, analyzed the data, performed statistical analyses and wrote the
manuscript. TD and LB designed experiments and edited the manuscript. SJ
designed and performed experiments. AS and JL performed HPLC. RB
provided MIF KO mice and edited the manuscript. All authors read and
approved the final manuscript.
Acknowledgements
This work was supported by the Swedish Research Council (grant 2009-4284,
2012-2229), Region of Scania state grants, the Crafoord Foundation, Michigan
State University and Van Andel Research Institute, Grand Rapids, Michigan
(LB), A. E. Berger, the Gyllenstiernska Krapperup and G&J Kock foundations,
the Royal Physiographic Society, and NIH AR049610.
Author details
1Translational Neuropsychiatry Unit, Department of Clinical Medicine, Aarhus
University, Risskov, Denmark. 2Clinical Memory Research Unit, Department of
Clinical Sciences, Lund University, Malmö, Sweden. 3Department of Psychiatry
and Behavioral Medicine, Michigan State University, Grand Rapids, MI, USA.
4Department of Medicine, Yale School of Medicine, New Haven, CT, USA.
5Department of Translational Science and Molecular Medicine, Michigan
State University, Grand Rapids, MI, USA. 6Experimental Neuroinflammation
Laboratory, Department of Experimental Medical Science, BMC, Lund
University, Lund, Sweden. 7Laboratory of Behavioral Medicine, Van Andel
Research Institute, Grand Rapids, MI, USA.
Received: 22 March 2015 Accepted: 24 August 2015
References
1. Weissman MM, Bland RC, Canino GJ, Faravelli C, Greenwald S, Hwu HG,
et al. Cross-national epidemiology of major depression and bipolar disorder.
JAMA. 1996;276(4):293–9.
2. Keller MB, Lavori PW, Mueller TI, Endicott J, Coryell W, Hirschfeld RM, et al.
Time to recovery, chronicity, and levels of psychopathology in major
depression. A 5-year prospective follow-up of 431 subjects. Arch Gen
Psychiatry. 1992;49(10):809–16.
3. Williams JM, Russell IT, Crane C, Russell D, Whitaker CJ, Duggan DS, et al.
Staying well after depression: trial design and protocol. BMC Psychiatry.
2010;10(1):23.
4. Capuron L, Fornwalt FB, Knight BT, Harvey PD, Ninan PT, Miller AH. Does
cytokine-induced depression differ from idiopathic major depression in
medically healthy individuals? J Affect Disord. 2009;119(1-3):181.
5. Capuron L, Ravaud A, Dantzer R. Early depressive symptoms in cancer
patients receiving interleukin 2 and/or interferon alfa-2b therapy. J Clin
Oncol. 2000;18(10):2143–51.
6. Raison CL, Borisov AS, Majer M, Drake DF, Pagnoni G, Woolwine BJ,
et al. Activation of central nervous system inflammatory pathways by
interferon-alpha: relationship to monoamines and depression. Biol
Psychiatry. 2009;65(4):296–303.
7. Raison CL, Demetrashvili M, Capuron L, Miller AH. Neuropsychiatric adverse
effects of interferon-alpha: recognition and management. CNS Drugs.
2005;19(2):105–23.
8. Bay-Richter C, Janelidze S, Hallberg L, Brundin L. Changes in behaviour and
cytokine expression upon a peripheral immune challenge. Behav Brain Res.
2011;222(1):193–9.
9. Dunn AJ, Swiergiel AH, de Beaurepaire R. Cytokines as mediators of
depression: what can we learn from animal studies? Neurosci Biobehav Rev.
2005;29(4-5):891–909.
10. Yirmiya R. Endotoxin produces a depressive-like episode in rats. Brain Res.
1996;711(1-2):163–74.
11. Connor TJ, Leonard BE. Depression, stress and immunological activation: the
role of cytokines in depressive disorders. Life Sci. 1998;62(7):583–606.
12. Hestad KA, Tonseth S, Stoen CD, Ueland T, Aukrust P. Raised plasma levels
of tumor necrosis factor alpha in patients with depression: normalization
during electroconvulsive therapy. J ECT. 2003;19(4):183–8.13. Thomas AJ, Davis S, Morris C, Jackson E, Harrison R, O’Brien JT. Increase in
interleukin-1beta in late-life depression. Am J Psychiatry. 2005;162(1):175–7.
14. Müller N, Schwarz MJ, Dehning S, Douche A, Cerovecki A, Goldstein-Müller B,
et al. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major
depression: results of a double-blind, randomized, placebo controlled, add-on
pilot study to reboxetine. Mol Psychiatry. 2006;11(7):680–4.
15. Bloom J, Al-Abed Y. MIF: mood improving/inhibiting factor? J Neuroinflammation.
2014;11:11.
16. Ohkawara T, Takeda H, Miyashita K, Nishiwaki M, Nakayama T, Taniguchi M,
et al. Regulation of Toll-like receptor 4 expression in mouse colon by
macrophage migration inhibitory factor. Histochem Cell Biol.
2006;125(5):575–82.
17. Das R, Subrahmanyan L, Yang IV, van Duin D, Levy R, Piecychna M,
et al. Functional polymorphisms in the gene encoding macrophage
migration inhibitory factor are associated with Gram-negative
bacteremia in older adults. J Infect Dis. 2014;209(5):764–8.
18. Carli C, Metz CN, Al-Abed Y, Naccache PH, Akoum A. Up-regulation of
cyclooxygenase-2 expression and prostaglandin E2 production in human
endometriotic cells by macrophage migration inhibitory factor: involvement
of novel kinase signaling pathways. Endocrinology. 2009;150(7):3128–37.
19. Calandra T, Bernhagen J, Metz CN, Spiegel LA, Bacher M, Donnelly T, et al.
MIF as a glucocorticoid-induced modulator of cytokine production. Nature.
1995;377(6544):68–71.
20. Fingerle-Rowson G, Koch P, Bikoff R, Lin X, Metz CN, Dhabhar FS, et al.
Regulation of macrophage migration inhibitory factor expression by
glucocorticoids in vivo. Am J Pathol. 2003;162(1):47–56.
21. Mitchell RA, Metz CN, Peng T, Bucala R. Sustained mitogen-activated
protein kinase (MAPK) and cytoplasmic phospholipase A2 activation by
macrophage migration inhibitory factor (MIF). Regulatory role in cell
proliferation and glucocorticoid action. J Biol Chem.
1999;274(25):18100–6.
22. Lue H, Kleemann R, Calandra T, Roger T, Bernhagen J. Macrophage
migration inhibitory factor (MIF): mechanisms of action and role in disease.
Microbes Infect. 2002;4(4):449–60.
23. Bucala R. Signal transduction. A most interesting factor. Nature.
2000;408(6809):146–7.
24. Cvetkovic I, Al-Abed Y, Miljkovic D, Maksimovic-Ivanic D, Roth J, Bacher M, et al.
Critical role of macrophage migration inhibitory factor activity in experimental
autoimmune diabetes. Endocrinology. 2005;146(7):2942–51.
25. Musil R, Schwarz MJ, Riedel M, Dehning S, Cerovecki A, Spellmann I, et al.
Elevated macrophage migration inhibitory factor and decreased transforming
growth factor-beta levels in major depression—no influence of celecoxib
treatment. J Affect Disord. 2011;134(1-3):217–25.
26. Edwards KM, Bosch JA, Engeland CG, Cacioppo JT, Marucha PT. Elevated
macrophage migration inhibitory factor (MIF) is associated with depressive
symptoms, blunted cortisol reactivity to acute stress, and lowered morning
cortisol. Brain Behav Immun. 2010;24(7):1202–8.
27. Cattaneo A, Gennarelli M, Uher R, Breen G, Farmer A, Aitchison KJ, et al.
Candidate genes expression profile associated with antidepressants response
in the GENDEP study: differentiating between baseline ‘predictors’ and
longitudinal ‘targets’. Neuropsychopharmacology. 2012;38:377–85.
28. Lu XT, Liu YF, Zhao L, Li WJ, Yang RX, Yan FF, et al. Chronic psychological
stress induces vascular inflammation in rabbits. Stress. 2012;16:87–98.
29. Conboy L, Varea E, Castro JE, Sakouhi-Ouertatani H, Calandra T, Lashuel HA,
et al. Macrophage migration inhibitory factor is critically involved in basal
and fluoxetine-stimulated adult hippocampal cell proliferation and in
anxiety, depression, and memory-related behaviors. Mol Psychiatry.
2011;16(5):533–47.
30. Moon HY, Kim SH, Yang YR, Song P, Yu HS, Park HG, et al. Macrophage
migration inhibitory factor mediates the antidepressant actions of voluntary
exercise. Proc Natl Acad Sci U S A. 2012;109(32):13094–9.
31. Willner P. Behavioural models in psychopharmacology: theoretical,
industrial, and clinical perspectives. UK: Cambridge University Press; 1991.
32. Porsolt RD, Le Pichon M, Jalfre M. Depression: a new animal model sensitive
to antidepressant treatments. Nature. 1977;266(5604):730–2.
33. Yan HC, Cao X, Das M, Zhu XH, Gao TM. Behavioral animal models of
depression. Neurosci Bull. 2010;26(4):327–37.
34. Papp M, Willner P, Muscat R. An animal model of anhedonia: attenuation of
sucrose consumption and place preference conditioning by chronic
unpredictable mild stress. Psychopharmacology (Berl). 1991;104(2):255–9.
Bay-Richter et al. Journal of Neuroinflammation  (2015) 12:163 Page 11 of 1135. Inacio AR, Ruscher K, Leng L, Bucala R, Deierborg T. Macrophage migration
inhibitory factor promotes cell death and aggravates neurologic deficits
after experimental stroke. J Cereb Blood Flow Metab. 2011;31(4):1093–106.
36. Petit-Demouliere B, Chenu F, Bourin M. Forced swimming test in mice: a review
of antidepressant activity. Psychopharmacology (Berl). 2005;177(3):245–55.
37. Steru L, Chermat R, Thierry B, Simon P. The tail suspension test: a new
method for screening antidepressants in mice. Psychopharmacology (Berl).
1985;85(3):367–70.
38. Cryan JF, Mombereau C, Vassout A. The tail suspension test as a model for
assessing antidepressant activity: review of pharmacological and genetic
studies in mice. Neurosci Biobehav Rev. 2005;29(4-5):571–625.
39. Pfaffl MW. A new mathematical model for relative quantification in real-time
RT-PCR. Nucleic Acids Res. 2001;29(9):e45.
40. McNamara RK, Sullivan J, Richtand NM, Jandacek R, Rider T, Tso P, et al.
Omega-3 fatty acid deficiency augments amphetamine-induced behavioral
sensitization in adult DBA/2J mice: relationship with ventral striatum
dopamine concentrations. Synapse. 2008;62(10):725–35.
41. Christian LM, Franco A, Iams JD, Sheridan J, Glaser R. Depressive symptoms
predict exaggerated inflammatory responses to an in vivo immune
challenge among pregnant women. Brain Behav Immun. 2010;24(1):49–53.
42. Cattaneo A, Gennarelli M, Uher R, Breen G, Farmer A, Aitchison KJ, et al.
Candidate genes expression profile associated with antidepressants
response in the GENDEP study: differentiating between baseline ‘predictors’
and longitudinal ‘targets’. Neuropsychopharmacology. 2013;38(3):377–85.
43. Katsuura S, Kamezaki Y, Yamagishi N, Kuwano Y, Nishida K, Masuda K, et al.
Circulating vascular endothelial growth factor is independently and
negatively associated with trait anxiety and depressive mood in healthy
Japanese university students. Int J Psychophysiol. 2011;81(1):38–43.
44. Owens M, Herbert J, Jones PB, Sahakian BJ, Wilkinson PO, Dunn VJ, et al.
Elevated morning cortisol is a stratified population-level biomarker for major
depression in boys only with high depressive symptoms. Proc Natl Acad Sci
U S A. 2014;111(9):3638–43.
45. Silverman MN, Sternberg EM. Glucocorticoid regulation of inflammation and
its functional correlates: from HPA axis to glucocorticoid receptor
dysfunction. Ann N Y Acad Sci. 2012;1261:55–63.
46. Stokes PE. The potential role of excessive cortisol induced by HPA
hyperfunction in the pathogenesis of depression. Eur
Neuropsychopharmacol. 1995;5(1):77–82.
47. Halbreich U, Lumley LA. The multiple interactional biological processes that
might lead to depression and gender differences in its appearance. J Affect
Disord. 1993;29(2-3):159–73.
48. Bucala R. MIF rediscovered: cytokine, pituitary hormone, and glucocorticoid-
induced regulator of the immune response. FASEB J. 1996;10(14):1607–13.
49. Garner JP. Stereotypies and other abnormal repetitive behaviors: potential
impact on validity, reliability, and replicability of scientific outcomes. ILAR J.
2005;46(2):106–17.
50. Clayton JA, Collins FS. Policy: NIH to balance sex in cell and animal studies.
Nature. 2014;509(7500):282–3.
51. Turtzo LC, Li J, Persky R, Benashski S, Weston G, Bucala R, et al. Deletion of
macrophage migration inhibitory factor worsens stroke outcome in female
mice. Neurobiol Dis. 2013;54:421–31.
52. DeVries AC, Joh HD, Bernard O, Hattori K, Hurn PD, Traystman RJ, et al.
Social stress exacerbates stroke outcome by suppressing Bcl-2 expression.
Proc Natl Acad Sci U S A. 2001;98(20):11824–8.
53. Dantzer R, O’Connor JC, Freund GG, Johnson RW, Kelley KW. From
inflammation to sickness and depression: when the immune system
subjugates the brain. Nat Rev Neurosci. 2008;9(1):46–56.
54. Fragoso YD, Frota ER, Lopes JS, Noal JS, Giacomo MC, Gomes S, et al. Severe
depression, suicide attempts, and ideation during the use of interferon beta
by patients with multiple sclerosis. Clin Neuropharmacol. 2010;33(6):312–6.
55. Shelton RC, Claiborne J, Sidoryk-Wegrzynowicz M, Reddy R, Aschner M,
Lewis DA, et al. Altered expression of genes involved in inflammation and
apoptosis in frontal cortex in major depression. Mol Psychiatry.
2011;16(7):751–62.
56. Oxenkrug G, Perianayagam M, Mikolich D, Requintina P, Shick L, Ruthazer R,
et al. Interferon-gamma (+874) T/A genotypes and risk of IFN-alpha-induced
depression. J Neural Transm. 2011;118(2):271–4.
57. O’connor JC, Andre C, Wang YX, Lawson MA, Szegedi SS, Lestage J, et al.
Interferon-gamma and tumor necrosis factor-alpha mediate the upregulation
of indoleamine 2,3-dioxygenase and the induction of depressive-like behavior
in mice in response to Bacillus Calmette-Guerin. J Neurosci. 2009;29(13):4200–9.58. Sperner-Unterweger B, Kohl C, Fuchs D. Immune changes and
neurotransmitters: possible interactions in depression? Prog
Neuropsychopharmacol Biol Psychiatry. 2012;48:268–76.
59. Nestler EJ, Carlezon Jr WA. The mesolimbic dopamine reward circuit in
depression. Biol Psychiatry. 2006;59(12):1151–9.
60. Berton O, McClung CA, Dileone RJ, Krishnan V, Renthal W, Russo SJ, et al.
Essential role of BDNF in the mesolimbic dopamine pathway in social
defeat stress. Science. 2006;311:864–8.
61. Krishnan V, Han MH, Graham DL, Berton O, Renthal W, Russo SJ, et al.
Molecular adaptations underlying susceptibility and resistance to social
defeat in brain reward regions. Cell. 2007;131(2):391–404.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
